GSK3B and Alzheimer disease: In a study published in 2019, Sharma et al. reported that reduced BVR-A protein levels impair the physical interaction between Akt and GSK-3β in aMCI and AD post-mortem cortical samples, thus reducing the Akt-mediated inhibition of GSK-3β [54] (Table 2).